Who are Induction- PF-06480605 150 mg SC Q4W's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chronic- PF-06480605 50 mg SC Q4W, Pf-07293893, Xeljanz, Xeljanz, Xeljanz, Abrocitinib Suspension F1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/induction-pf-06480605-150-mg-sc-q4w.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Induction- PF-06480605 150 mg SC Q4W — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induction- PF-06480605 150 mg SC Q4W (induction-pf-06480605-150-mg-sc-q4w) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

marketed JAK inhibitor JAK pathway Immunology Live · refreshed every 30 min

Target snapshot

Induction- PF-06480605 150 mg SC Q4W (induction-pf-06480605-150-mg-sc-q4w) — Pfizer. PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Induction- PF-06480605 150 mg SC Q4W TARGET	induction-pf-06480605-150-mg-sc-q4w	Pfizer	marketed	JAK inhibitor	JAK pathway
Chronic- PF-06480605 50 mg SC Q4W	chronic-pf-06480605-50-mg-sc-q4w	Pfizer	marketed	JAK inhibitor	JAK pathway
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Xeljanz	tofacitinib	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Abrocitinib Suspension F1	abrocitinib-suspension-f1	Pfizer	marketed	JAK inhibitor	JAK1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

Pfizer · 19 drugs in this class
Aclaris Therapeutics, Inc. · 2 drugs in this class
Beijing Friendship Hospital · 2 drugs in this class
Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
CAGE Bio Inc. · 1 drug in this class
CTI BioPharma · 1 drug in this class
Celgene · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class
LEO Pharma · 1 drug in this class
McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Induction- PF-06480605 150 mg SC Q4W — Competitive Intelligence Brief. https://druglandscape.com/ci/induction-pf-06480605-150-mg-sc-q4w. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab